

AVI BioPharma to Present Company Overview at the Lazard Capital Markets 8th Annual Healthcare Conference

November 8, 2011 8:08 AM ET

Webcast Accessible via AVI Website

BOTHELL, WA, Nov 08, 2011 (MARKETWIRE via COMTEX) --

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that the Company is scheduled to present at the Lazard Capital Markets 8th Annual Healthcare Conference in New York, NY, on Tuesday, November 15, at 2:00 p.m. Eastern Time. Chris Garabedian, AVI's President and CEO, will provide a company overview.

The presentation will be webcast live under the events section of AVI's website at www.avibio.com and will be archived there following the presentation for 90 days. Please connect to AVI's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, the Company is able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, AVI's technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging its highly differentiated RNA-based technology platform, AVI has built a pipeline of potentially transformative therapeutic agents, including eteplirsen, which is in clinical development for the treatment of Duchenne muscular dystrophy, and multiple drug candidates that are in clinical development for the treatment of infectious disease. For more information, please visit www.avibio.com.

AVI Media and Investor Contact:

Erin Cox
Manager, Corporate Communications and Investor Relations
425.354.5140
[Email Contact](#)

AVI Media Contact:

David Schull
Russo Partners
212.845.4271
[Email Contact](#)

SOURCE: AVI BioPharma, Inc.